Related Experiment Video
Updated: Aug 12, 2025
06:33
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
1.3K
Microbiota and Hematological Diseases.
1Laboratory of Clinical-Chemistry, Hematology and Microbiology, (ASST-Valle Olona) Gallarate Hospital, Gallarate, Varese, Italy.
International Journal of Hematology-Oncology and Stem Cell Research
|January 25, 2023
Summary
Human gut microbiota dysbiosis, an imbalance in microbial communities, is linked to various hematologic disorders and impacts treatment effectiveness. Short-chain fatty acids mediate these effects, influencing immune responses and patient outcomes.
Area of Science:
- Microbiology
- Immunology
- Hematology
Background:
- The human microbiota plays a crucial role in host metabolism and immune system regulation.
- Microbiota alterations, known as dysbiosis, are associated with numerous pathologies.
- Short-chain fatty acids (SCFAs) produced by microbial metabolism act as key immune mediators.
Purpose of the Study:
- To explore the connection between human microbiota dysbiosis and hematologic conditions.
- To investigate the influence of dysbiosis on the efficacy of various hematologic therapies.
Main Methods:
- Review of existing literature on microbiota, dysbiosis, and hematology.
- Analysis of the role of short-chain fatty acids in immune modulation within hematologic contexts.
- Examination of dysbiosis impact on non-neoplastic and neoplastic hematologic disorders.
Main Results:
- Dysbiosis is implicated as a predisposing factor for both non-neoplastic hematologic disorders (e.g., iron deficiency anemia, thrombosis) and neoplastic conditions (e.g., lymphomas, leukemias).
- Microbiota dysbiosis can significantly affect the efficacy of treatments such as iron supplementation, chemotherapy, immunotherapy, and hematopoietic stem cell transplantation.
- The immune-mediating role of SCFAs is highlighted in the context of dysbiosis-related hematologic issues.
Conclusions:
- Microbiota dysbiosis is a significant factor in the development and progression of hematologic diseases.
- Modulating the gut microbiota may offer novel therapeutic strategies in hematology.
- Understanding dysbiosis is critical for optimizing treatment outcomes in patients with hematologic disorders.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
385
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
385
01:01Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
01:21Hematopoiesis
5.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.5K
01:29Microorganisms in Medicine and Therapeutics
111
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
111
01:26Factors Affecting the Risk of Infection
12.1K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
12.1K
01:28Role of Hematopoietic Growth Factors
1.5K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.5K